Neurocrine (NBIX) Gets a Buy Rating from Barclays


Barclays analyst Geoff Meacham maintained a Buy rating on Neurocrine (NBIX) yesterday and set a price target of $110. The company’s shares closed yesterday at $85.55.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.4% and a 56.3% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Bausch Health Companies Inc, and Kiniksa Pharmaceuticals Ltd.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $106.78 average price target, a 24.8% upside from current levels. In a report issued on March 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $102 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $126.98 and a one-year low of $64.72. Currently, Neurocrine has an average volume of 939.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts